Global Ophthalmol Drug Market
Global Ophthalmol Drug Market

Ophthalmol Drug Comprehensive Study by Type (Antiseptics, Corticosteroids, Anit- Microbial, Fluoroquinolone Antibiotic, Others), Administration (Oral, Intravenous, Parenteral), Indication (Cataract, Vitreoretinal, Glaucoma, Refractive Error, Others) Players and Region - Global Market Outlook to 2026

Ophthalmol Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2021 Edition 240 Pages 190 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Ophthalmol Drug Market Scope
With the recent approval of numerous novel medications to lower IOP, glaucoma management has become a hot topic in optometry. Antibiotics for the eyes are used to treat infections caused by gram-positive bacteria like Staphylococci, Streptococci, and Escherichia coli, as well as gram-negative bacteria like Chlamydia trachomatis. Bacterial eye infections are treated with ophthalmic medicines. The ageing population means that age-related eye illnesses, such as age-related macular degeneration, are becoming more common. If discovered early, these eye illnesses can be successfully treated and controlled with currently available therapies and medications. The Ophthalmol medicines market is be propelled by technological advancements, growing prevalence rates of refractive error, cataract, and glaucoma, rising need for diagnostic methods.

The Ophthalmol Drug market study is segmented by Type (Antiseptics, Corticosteroids, Anit- Microbial, Fluoroquinolone Antibiotic and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States & Japanese Players will contribute to the maximum growth of Global Ophthalmol Drug market throughout the predicted period.

Alcon (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Allergan Inc. (United States), Merck KGaA (Germany), Pfizer Inc. (United States), Santen Pharmaceutical Co., Ltd. (Japan), Bausch & Lomb, Inc. (Canada), Carl Zeiss Meditec (Germany), Essilor (France) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Nidek Co., Ltd (Japan) and Topcon (Japan).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Ophthalmol Drug market by Type, Application and Region.

On the basis of geography, the market of Ophthalmol Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies

On 7th January, 2019 - Kala Pharmaceuticals (Leading Biopharmaceutical Company) Launched “INVELTYS” (Loteprednol Etabonate Ophthalmic Suspension). INVELTYS is The First and Only Twice-Daily Ocular Corticosteroid Approved for The Treatment of Ocular Surgery-Related Inflammation and Pain.


Market Trend
  • Rising Geriatric Population

Market Drivers
  • Prevalence of Age-Related Macular Degeneration (AMD) and Cataract
  • High Investment in Healthcare R&D

Opportunities
  • Growth in Healthcare Infrastructures Across Asian Regions

Restraints
  • Low Awareness
  • High-Cost Expenses

Challenges
  • Lack of Trained Professionals
  • Fierce Competitive Pressure


Key Target Audience
Ophthalmol Drug Manufactures, New Entrants and Investors, Ophthalmol Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Ophthalmol Drug Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Antiseptics
  • Corticosteroids
  • Anit- Microbial
  • Fluoroquinolone Antibiotic
  • Others
By Administration
  • Oral
  • Intravenous
  • Parenteral

By Indication
  • Cataract
  • Vitreoretinal
  • Glaucoma
  • Refractive Error
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Age-Related Macular Degeneration (AMD) and Cataract
      • 3.2.2. High Investment in Healthcare R&D
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals
      • 3.3.2. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ophthalmol Drug, by Type, Administration, Indication and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Ophthalmol Drug (Value)
      • 5.2.1. Global Ophthalmol Drug by: Type (Value)
        • 5.2.1.1. Antiseptics
        • 5.2.1.2. Corticosteroids
        • 5.2.1.3. Anit- Microbial
        • 5.2.1.4. Fluoroquinolone Antibiotic
        • 5.2.1.5. Others
      • 5.2.2. Global Ophthalmol Drug by: Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Intravenous
        • 5.2.2.3. Parenteral
      • 5.2.3. Global Ophthalmol Drug by: Indication (Value)
        • 5.2.3.1. Cataract
        • 5.2.3.2. Vitreoretinal
        • 5.2.3.3. Glaucoma
        • 5.2.3.4. Refractive Error
        • 5.2.3.5. Others
      • 5.2.4. Global Ophthalmol Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Ophthalmol Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alcon (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck KGaA (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Santen Pharmaceutical Co., Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bausch & Lomb, Inc. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Carl Zeiss Meditec (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Essilor (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Ophthalmol Drug Sale, by Type, Administration, Indication and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Ophthalmol Drug (Value)
      • 7.2.1. Global Ophthalmol Drug by: Type (Value)
        • 7.2.1.1. Antiseptics
        • 7.2.1.2. Corticosteroids
        • 7.2.1.3. Anit- Microbial
        • 7.2.1.4. Fluoroquinolone Antibiotic
        • 7.2.1.5. Others
      • 7.2.2. Global Ophthalmol Drug by: Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Intravenous
        • 7.2.2.3. Parenteral
      • 7.2.3. Global Ophthalmol Drug by: Indication (Value)
        • 7.2.3.1. Cataract
        • 7.2.3.2. Vitreoretinal
        • 7.2.3.3. Glaucoma
        • 7.2.3.4. Refractive Error
        • 7.2.3.5. Others
      • 7.2.4. Global Ophthalmol Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ophthalmol Drug: by Type(USD Million)
  • Table 2. Ophthalmol Drug Antiseptics , by Region USD Million (2015-2020)
  • Table 3. Ophthalmol Drug Corticosteroids , by Region USD Million (2015-2020)
  • Table 4. Ophthalmol Drug Anit- Microbial , by Region USD Million (2015-2020)
  • Table 5. Ophthalmol Drug Fluoroquinolone Antibiotic , by Region USD Million (2015-2020)
  • Table 6. Ophthalmol Drug Others , by Region USD Million (2015-2020)
  • Table 7. Ophthalmol Drug: by Administration(USD Million)
  • Table 8. Ophthalmol Drug Oral , by Region USD Million (2015-2020)
  • Table 9. Ophthalmol Drug Intravenous , by Region USD Million (2015-2020)
  • Table 10. Ophthalmol Drug Parenteral , by Region USD Million (2015-2020)
  • Table 11. Ophthalmol Drug: by Indication(USD Million)
  • Table 12. Ophthalmol Drug Cataract , by Region USD Million (2015-2020)
  • Table 13. Ophthalmol Drug Vitreoretinal , by Region USD Million (2015-2020)
  • Table 14. Ophthalmol Drug Glaucoma , by Region USD Million (2015-2020)
  • Table 15. Ophthalmol Drug Refractive Error , by Region USD Million (2015-2020)
  • Table 16. Ophthalmol Drug Others , by Region USD Million (2015-2020)
  • Table 17. South America Ophthalmol Drug, by Country USD Million (2015-2020)
  • Table 18. South America Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 19. South America Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 20. South America Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 21. Brazil Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 22. Brazil Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 23. Brazil Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 24. Argentina Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 25. Argentina Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 26. Argentina Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 27. Rest of South America Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 29. Rest of South America Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 30. Asia Pacific Ophthalmol Drug, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 33. Asia Pacific Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 34. China Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 35. China Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 36. China Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 37. Japan Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 38. Japan Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 39. Japan Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 40. India Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 41. India Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 42. India Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 43. South Korea Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 44. South Korea Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 45. South Korea Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 46. Taiwan Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 47. Taiwan Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 48. Taiwan Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 49. Australia Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 50. Australia Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 51. Australia Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 55. Europe Ophthalmol Drug, by Country USD Million (2015-2020)
  • Table 56. Europe Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 57. Europe Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 58. Europe Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 59. Germany Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 60. Germany Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 61. Germany Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 62. France Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 63. France Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 64. France Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 65. Italy Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 66. Italy Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 67. Italy Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 68. United Kingdom Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 70. United Kingdom Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 71. Netherlands Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 72. Netherlands Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 73. Netherlands Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 74. Rest of Europe Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 76. Rest of Europe Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 77. MEA Ophthalmol Drug, by Country USD Million (2015-2020)
  • Table 78. MEA Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 79. MEA Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 80. MEA Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 81. Middle East Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 82. Middle East Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 83. Middle East Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 84. Africa Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 85. Africa Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 86. Africa Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 87. North America Ophthalmol Drug, by Country USD Million (2015-2020)
  • Table 88. North America Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 89. North America Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 90. North America Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 91. United States Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 92. United States Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 93. United States Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 94. Canada Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 95. Canada Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 96. Canada Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 97. Mexico Ophthalmol Drug, by Type USD Million (2015-2020)
  • Table 98. Mexico Ophthalmol Drug, by Administration USD Million (2015-2020)
  • Table 99. Mexico Ophthalmol Drug, by Indication USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Ophthalmol Drug: by Type(USD Million)
  • Table 111. Ophthalmol Drug Antiseptics , by Region USD Million (2021-2026)
  • Table 112. Ophthalmol Drug Corticosteroids , by Region USD Million (2021-2026)
  • Table 113. Ophthalmol Drug Anit- Microbial , by Region USD Million (2021-2026)
  • Table 114. Ophthalmol Drug Fluoroquinolone Antibiotic , by Region USD Million (2021-2026)
  • Table 115. Ophthalmol Drug Others , by Region USD Million (2021-2026)
  • Table 116. Ophthalmol Drug: by Administration(USD Million)
  • Table 117. Ophthalmol Drug Oral , by Region USD Million (2021-2026)
  • Table 118. Ophthalmol Drug Intravenous , by Region USD Million (2021-2026)
  • Table 119. Ophthalmol Drug Parenteral , by Region USD Million (2021-2026)
  • Table 120. Ophthalmol Drug: by Indication(USD Million)
  • Table 121. Ophthalmol Drug Cataract , by Region USD Million (2021-2026)
  • Table 122. Ophthalmol Drug Vitreoretinal , by Region USD Million (2021-2026)
  • Table 123. Ophthalmol Drug Glaucoma , by Region USD Million (2021-2026)
  • Table 124. Ophthalmol Drug Refractive Error , by Region USD Million (2021-2026)
  • Table 125. Ophthalmol Drug Others , by Region USD Million (2021-2026)
  • Table 126. South America Ophthalmol Drug, by Country USD Million (2021-2026)
  • Table 127. South America Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 128. South America Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 129. South America Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 130. Brazil Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 131. Brazil Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 132. Brazil Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 133. Argentina Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 134. Argentina Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 135. Argentina Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 136. Rest of South America Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 137. Rest of South America Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 138. Rest of South America Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 139. Asia Pacific Ophthalmol Drug, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 141. Asia Pacific Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 142. Asia Pacific Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 143. China Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 144. China Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 145. China Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 146. Japan Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 147. Japan Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 148. Japan Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 149. India Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 150. India Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 151. India Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 152. South Korea Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 153. South Korea Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 154. South Korea Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 155. Taiwan Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 156. Taiwan Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 157. Taiwan Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 158. Australia Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 159. Australia Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 160. Australia Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 164. Europe Ophthalmol Drug, by Country USD Million (2021-2026)
  • Table 165. Europe Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 166. Europe Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 167. Europe Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 168. Germany Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 169. Germany Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 170. Germany Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 171. France Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 172. France Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 173. France Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 174. Italy Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 175. Italy Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 176. Italy Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 177. United Kingdom Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 178. United Kingdom Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 179. United Kingdom Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 180. Netherlands Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 181. Netherlands Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 182. Netherlands Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 183. Rest of Europe Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 184. Rest of Europe Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 185. Rest of Europe Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 186. MEA Ophthalmol Drug, by Country USD Million (2021-2026)
  • Table 187. MEA Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 188. MEA Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 189. MEA Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 190. Middle East Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 191. Middle East Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 192. Middle East Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 193. Africa Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 194. Africa Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 195. Africa Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 196. North America Ophthalmol Drug, by Country USD Million (2021-2026)
  • Table 197. North America Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 198. North America Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 199. North America Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 200. United States Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 201. United States Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 202. United States Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 203. Canada Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 204. Canada Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 205. Canada Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 206. Mexico Ophthalmol Drug, by Type USD Million (2021-2026)
  • Table 207. Mexico Ophthalmol Drug, by Administration USD Million (2021-2026)
  • Table 208. Mexico Ophthalmol Drug, by Indication USD Million (2021-2026)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ophthalmol Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Ophthalmol Drug: by Administration USD Million (2015-2020)
  • Figure 6. Global Ophthalmol Drug: by Indication USD Million (2015-2020)
  • Figure 7. South America Ophthalmol Drug Share (%), by Country
  • Figure 8. Asia Pacific Ophthalmol Drug Share (%), by Country
  • Figure 9. Europe Ophthalmol Drug Share (%), by Country
  • Figure 10. MEA Ophthalmol Drug Share (%), by Country
  • Figure 11. North America Ophthalmol Drug Share (%), by Country
  • Figure 12. Global Ophthalmol Drug share by Players 2020 (%)
  • Figure 13. Global Ophthalmol Drug share by Players (Top 3) 2020(%)
  • Figure 14. Global Ophthalmol Drug share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Alcon (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Alcon (Switzerland) Revenue: by Geography 2020
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Allergan Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Allergan Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Santen Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Santen Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 28. Bausch & Lomb, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Bausch & Lomb, Inc. (Canada) Revenue: by Geography 2020
  • Figure 30. Carl Zeiss Meditec (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Carl Zeiss Meditec (Germany) Revenue: by Geography 2020
  • Figure 32. Essilor (France) Revenue, Net Income and Gross profit
  • Figure 33. Essilor (France) Revenue: by Geography 2020
  • Figure 34. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 36. Global Ophthalmol Drug: by Type USD Million (2021-2026)
  • Figure 37. Global Ophthalmol Drug: by Administration USD Million (2021-2026)
  • Figure 38. Global Ophthalmol Drug: by Indication USD Million (2021-2026)
  • Figure 39. South America Ophthalmol Drug Share (%), by Country
  • Figure 40. Asia Pacific Ophthalmol Drug Share (%), by Country
  • Figure 41. Europe Ophthalmol Drug Share (%), by Country
  • Figure 42. MEA Ophthalmol Drug Share (%), by Country
  • Figure 43. North America Ophthalmol Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Alcon (Switzerland)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Allergan Inc. (United States)
  • Merck KGaA (Germany)
  • Pfizer Inc. (United States)
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Bausch & Lomb, Inc. (Canada)
  • Carl Zeiss Meditec (Germany)
  • Essilor (France)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Nidek Co., Ltd (Japan) , Topcon (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation